HYBRID EVENT: Join us in person in Tokyo, Japan or attend virtually from anywhere.
Gastrointestinal Stromal Tumor (GIST) is a rare type of cancer that originates in the gastrointestinal (GI) tract, which includes the stomach, intestines, and other digestive organs. GISTs are unique as they typically develop in the interstitial cells of Cajal, specialized cells that regulate the contractions of the GI tract. These tumors are often associated with genetic mutations, with the majority being driven by mutations in the KIT or PDGFRA genes. GISTs can occur at any age, but they are most commonly diagnosed in individuals between 50 and 70 years old. Symptoms of GISTs vary depending on the tumor's size and location within the GI tract. Some individuals may experience abdominal pain, gastrointestinal bleeding, or a palpable mass in the abdomen. However, GISTs can also be asymptomatic and discovered incidentally during diagnostic tests for other conditions. Diagnosis typically involves imaging studies such as CT scans, MRIs, or endoscopy, along with a biopsy to confirm the presence of a GIST. Treatment options for GISTs often include surgical removal of the tumor, targeted therapy with tyrosine kinase inhibitors, and, in some cases, chemotherapy. Prognosis for GISTs is influenced by various factors, including the tumor size, mitotic rate, and location. While some GISTs may have a relatively indolent course, others can be aggressive. Regular follow-up with healthcare providers is essential for monitoring the disease and adjusting the treatment plan as needed. Overall, GISTs represent a unique subset of gastrointestinal cancers, and ongoing research is focused on understanding the underlying genetic mechanisms and developing targeted therapies to improve outcomes for individuals diagnosed with this rare malignancy.
